Medaffcon and EasyHTA Develop New Tools for Health Economic Assessment
Medaffcon and EasyHTA are developing new ways to make health economic assessments faster and more transparent.
Latest News
Follow us on LinkedIn to stay up-to-date!
Latest articles
-
-
Medaffcon Posters at ISPOR: New Insights into Cancer Care and Technology-Assisted Homecare
Three new studies based on Medaffcon’s CORE datasets provide fresh insights into cancer care, examining treatment-related time burden, survival in the HUS region, and the relationship between education and cancer survival.
-
Medaffcon Explored Transportability of Evidence Between Finland and the United States
When local evidence is insufficient to support decision-making, research findings and real-world evidence generated elsewhere may help fill the gap.
-
The National Assessment and Decision-Making Model for Medicines Will be Developed Gradually by 2029
Finland is currently developing a national assessment and decision-making model for medicines.
-
The Transformation of the Pharmaceutical Industry Is Putting Pressure on Finland and Europe
Companies are becoming increasingly selective about where they launch new medicines and where they invest in research.
-
Thank You, Tomppa: Celebrating a Career Defined by People, Persistence and Positivity
Medaffcon’s Sales Lead Tomi "Tomppa" Vahevaara will retire on October 1st 2026. Tomppa leaves behind an exceptionally long career in the pharmaceutical industry spanning 45 years.
Latest in Real-World Evidence
-
Data gap analysis identifies what information about a medicinal product is still needed
In a data gap analysis, gaps in the available information of the therapy area and data on a medicinal product are mapped and assessed against regulatory, scientific, and business requirements.
-
Medaffcon Makes Medtech Measurable When Data Determines Market Access
Medaffcon brings to the health technology market the kind of effectiveness and cost-conscious thinking well established in the pharmaceutical industry.
-
Finland Introduces a National Health Data Space Model – The Role of Industry Still Needs Clarification
The objective is to improve access to health data for research and innovation, but the proposal raises concerns about increased administrative burden and the role of industry within the model.
-
Applying Transportability to Strengthen Pharma Evidence in the Nordics
Transportability and generalizability refer to the ability to apply evidence from a single study to different patient populations, clinical settings, or geographical regions.
-
The Secondary Use Act Will Be Reformed in 2026, Streamlining the Use of Data in Research
The reform of the Secondary Use Act will establish a new decentralised process, in parallel to the current centralised permit model in which Findata grants all data permits.
-
Finland Leads the Way Toward the EHDS, but Local Readiness Remains Limited
Finland is moving toward the European Health Data Space (EHDS) with strong national systems, but local readiness, funding, and interoperability remain challenges.
Latest in Market Access
-
The National Assessment and Decision-Making Model for Medicines Will be Developed Gradually by 2029
Finland is currently developing a national assessment and decision-making model for medicines.
-
Outsourcing Renewal Applications Frees Up Internal Resources
Medaffcon prepares around 25–30 renewal applications each year for approximately 10–15 clients. The volume ensures well-established routines and consistently high quality.
-
A Valuable Drug Portfolio May Remain Underutilised
Pharmaceutical companies’ product portfolios are valuable assets, yet they may remain underutilised. How to unlock the full potential of a drug portfolio?
-
Trump’s MFN Drug Pricing Policy Is Reshaping Pharmaceutical Markets
The United States is seeking to curb pharmaceutical expenditure by incorporating international price referencing into public health insurance programs.
-
Medaffcon Makes Medtech Measurable When Data Determines Market Access
Medaffcon brings to the health technology market the kind of effectiveness and cost-conscious thinking well established in the pharmaceutical industry.
-
Medaffcon Contributes to the Public Good through Academic Collaboration
While the majority of Medaffcon’s revenue comes from the pharmaceutical industry, the company’s activities are not limited only to commercial projects. At any given time, several academic projects may be ongoing.
Latest in Data Science
-
Medaffcon Explored Transportability of Evidence Between Finland and the United States
When local evidence is insufficient to support decision-making, research findings and real-world evidence generated elsewhere may help fill the gap.
-
Target trial emulation enables treatment comparisons based on real-world data
TTE is particularly valuable when there's a need to directly compare two treatments using real‑world data, especially when such comparisons have not been evaluated in RCTs.
-
Applying Transportability to Strengthen Pharma Evidence in the Nordics
Transportability and generalizability refer to the ability to apply evidence from a single study to different patient populations, clinical settings, or geographical regions.
-
Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
-
Data Team is the Backbone of Medaffcon, Ensuring the Reliability of Research Results
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in RWE studies.
-
Medaffcon’s Machine Learning Algorithm Adapts to Various Research Needs
The algorithm was originally developed to extract smoking status from patient texts with purpose to analyze the effects of smoking on postoperative complications. Today, it is also being utilized in lung cancer research.
Study summaries
-
A Study on Waldenström’s Macroglobulinemia Demonstrates the Concrete Potential of Registry Research
The study generated significant new insights into the epidemiology, treatment, and prognosis of the rare blood cancer Waldenström’s macroglobulinemia.
-
Hospital data enabled a comprehensive RWE study on the treatment of complex lung cancer
The RWE study examined the treatment of patients with metastatic NSCLC, illustrating how treatment practices have changed from the first years of immunotherapy to present day.
-
New Studies Confirm Urgent Need to Enhance Management of Diabetes and Diabetic Kidney Disease in Finland
The monitoring and diagnosis of diabetic kidney disease are often insufficient in Finland. This is confirmed by two real-world evidence (RWE) studies.
-
Early initiation of biologic treatment in psoriasis helps prevent the cumulative burden of disease
A large proportion of patients with psoriasis need to switch biologic treatment after initiation. This finding emerges from two RWE studies focusing on plaque psoriasis and psoriatic arthritis.
-
Medaffcon’s CORE Data Shows: Hospital Care Costs Declining, PD-L1 Testing and Immuno-Oncology Treatments Increasing in the HUS Region of Finland
The studies are based on Medaffcon’s Collaboration Research (CORE) dataset – a unique research platform.
-
Overall survival among SCT patients with multiple myeloma has improved between 2013 and 2022
This Finnish registry-based study investigated the development of treatment practices and patient outcomes between 2013 and 2022.
Most popular articles
-
The Transformation of the Pharmaceutical Industry Is Putting Pressure on Finland and Europe
Companies are becoming increasingly selective about where they launch new medicines and where they invest in research.
-
Trump’s MFN Drug Pricing Policy Is Reshaping Pharmaceutical Markets
The United States is seeking to curb pharmaceutical expenditure by incorporating international price referencing into public health insurance programs.
-
Digital contraception is a cost-effective alternative to hormonal contraception
Digital solutions challenge established perceptions of what constitutes acceptable contraceptive methods and which health benefits are considered measurable.
-
The Nordics Should Collaborate in the Life Science Sector
Access times to medicines vary greatly between European countries, and delays in oncology drugs in particular are increasing.
-
Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
-
The Demand for Outsourced Experts is Growing in Pharmaceutical Companies
Medaffcon provides skilled temporary workforce solutions for its client companies. An outsourced expert is a flexible solution to address a company's short-term resourcing challenges.
-
Payers Expect Clearer Demonstration of Health Technology Benefits
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
-
Medaffcon’s Patient Dynamics Tool Helps Focus and Find the Right Actions
Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
-
Pharmaceutical Pricing and Market Access of Medicine Products in Finland
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes these two routes and provides information of the market access options and pricing system in Finland. Updated annually.